CASI Pharmaceuticals Files 6-K, Incorporates Exhibits
Ticker: CASIF · Form: 6-K · Filed: Sep 26, 2025 · CIK: 1962738
Sentiment: neutral
Topics: regulatory-filing, registration-statement
TL;DR
CASI Pharma filed a 6-K on 9/26, incorporating exhibits into F-3 registration. Old name was CASI Pharma Holdings.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on September 26, 2025, reporting for the month of September 2025. This filing incorporates by reference information from Exhibits 99.1 into the Company's Registration Statements on Form F-3 (File No. 333-2839). The company was formerly known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023.
Why It Matters
This filing indicates ongoing regulatory reporting and potential updates to the company's registration statements, which could affect investor information and future capital-raising activities.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previously disclosed information and does not appear to contain new material events or financial disclosures.
Key Numbers
- 333-2839 — Registration Statement File Number (Information incorporated into this Form F-3 registration statement.)
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer
- CASI Pharmaceuticals Holdings, Inc. (company) — Former Company Name
- September 26, 2025 (date) — Filing Date
- Form F-3 (document) — Incorporated by Reference
- 001-41666 (identifier) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K is to report for the month of September 2025 and to incorporate by reference information from Exhibits 99.1 into the Company's Registration Statements on Form F-3.
When was CASI Pharmaceuticals, Inc. formerly known as CASI Pharmaceuticals Holdings, Inc.?
The company was formerly known as CASI Pharmaceuticals Holdings, Inc. until January 18, 2023.
What is the SEC file number for CASI Pharmaceuticals, Inc.?
The SEC file number for CASI Pharmaceuticals, Inc. is 001-41666.
What type of registration statement is being referenced in the filing?
The filing references the Company's Registration Statements on Form F-3.
What is the principal executive office address of CASI Pharmaceuticals, Inc.?
The principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
Filing Stats: 234 words · 1 min read · ~1 pages · Grade level 11 · Accepted 2025-09-26 09:15:17
Filing Documents
- tm2527019d1_6k.htm (6-K) — 10KB
- tm2527019d1_ex99-1.htm (EX-99.1) — 14KB
- tm2527019d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-25-093616.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ David Cory Name: David Cory Title: CEO Date: September 26, 2025